Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals

Philip M. Grant, Douglas Kitch, Grace A. McComsey, Ann C. Collier, Susan L. Koletar, Kristine M. Erlandson, Michael T. Yin, Benedetta Bartali, Belinda Ha, Kathy Melbourne, Todd T. Brown

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV-or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.

Original languageEnglish (US)
Pages (from-to)607-611
Number of pages5
JournalJournal of Infectious Diseases
Issue number4
StatePublished - Aug 15 2016


  • Administration and dosage
  • Adverse effects
  • Anti-HIV agents
  • Bone density
  • Drug therapy/virology
  • HIV infections

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals'. Together they form a unique fingerprint.

Cite this